Skip to main content
. Author manuscript; available in PMC: 2023 Mar 1.
Published in final edited form as: Gastroenterology. 2021 Nov 13;162(3):828–843.e11. doi: 10.1053/j.gastro.2021.11.015

Figure 4. Genetic colocalization between essential fatty acids, FADS1/2 and IBD risk.

Figure 4.

A) Regional association plots of the genetic associations at the Chr11 position which contains the FADS locus indicate co-localization of IBD risk and levels of serum metabolites (ids 33228, 36600, 42449, 42450, 52446, 52462, 52603, 52687, 52689, 54960, 54961, 57450, and 57467). Genome-wide significance threshold: 5E-8/1300=3.8E-11. B) Graph of the results of genetic colocalization analysis, testing for a shared genetic locus controlling serum levels of various omega-6 containing PUFAs with risk of IBD, CD or UC. Also, plotted are the results of the MR analysis including the OR and Fieller’s confidence intervals. Metabolites on the vertical axis, estimates on the horizontal axis, genetic regions in vertical stripes. See Figure Legend 3 for details. C) A schema showing putative causal associations (solid lines) and statistical associations (dashed line) with edges labeled according to the data sources. Evidence for the association between genetic variation and mRNA transcripts was gathered from published eQTL studies or GTEx database searches. D) Biochemical schema of the metabolism of omega-6 and omega-3 PUFAs with the position of FADS1 and FADS2. The bottom image summarizes results of MR which predicts that elevated serum levels of the precursor omega-6 PUFA increase risk of CD, whereas decreased levels of the PUFA end-products are protective.